What ValueGen.AI Produces
HEOR and market access outputs in formats your stakeholders already use.
Evidence, modeling, and submission-ready narratives
Cost-Effectiveness Model
Markov or decision-tree CEA with PSA, tornado diagrams, ICER outputs, and country-specific threshold analysis.
Budget Impact Model
Payer-level BIM with market uptake, patient share, cost offsets, and scenario toggles.
Online Interactive Model
Browser-based model with sliders and real-time scenario exploration — shareable with payers and HTA bodies.
Landscape Assessment Report
Comprehensive disease-area landscape generated in 48 hours: HTA history, guidelines, and published evidence across 7 markets.
Evidence Gap Analysis
Structured report ranking evidence gaps by strategic priority with recommendations for clinical study design.
Regulatory Submission Summary
Concise clinical evidence narrative for FDA, EMA, or HTA dossier submissions with source citations.
Payer-ready dossiers, dashboards, and briefings
HTA Intelligence Dashboard
Live dashboard tracking HTA decisions, payer positions, and reimbursement status across NICE, G-BA, HAS, ICER, CADTH, AIFA, AEM.
Global Value Dossier
Structured dossier narrative — clinical summary, PICOTS, economic model narrative, and appendices aligned to each HTA body template.
Payer Objection Handler
Q&A document with anticipated payer objections and structured counterarguments on efficacy, durability, and pricing.
Reimbursement Landscape Report
Multi-country reimbursement summary covering coverage, formulary placement, access restrictions, and price benchmarking.
Payer Briefing Note
1–2 page briefing synthesizing clinical evidence, budget impact, and access context for field teams ahead of payer meetings.
Country Adaptation Package
Localized model and narrative adapted to country-specific epidemiology, unit costs, comparators, and HTA methodology.
Tell Us What You Need to Deliver
From a CEA in Excel to a country-adapted value dossier — we'll show you the fastest path with ValueGen.AI.
Request a Demo